Institutional Investment Growth
Meiji Yasuda Expands U.S. Holdings Amid Growing Institutional Investment Activity
Anonymous
Key Points
1
Edwards Lifesciences insiders exercised stock sales in August: VP Annette Bruls sold 2,644 EW shares at an average price of $89.98 (about $237,907), leaving her with 17,984 shares worth roughly $1.62 million; this represented a 12.82% decrease in ownership. Separately, VP Daniel J. Lippis sold 619 EW shares on August 11 at an average price of $92.03 (about $56,967), leaving him with 40,034 shares valued at about $3.68 million; both trades were disclosed via SEC filings and, for Lippis, executed under a pre‑arranged Rule 10b5‑1 plan.
2
Bloom Energy insider activity shows additional executive turnover: Satish Chitoori sold 2,837 BE shares on June 16 at an average price of $289.11, totaling about $820,205; post‑sale, Chitoori owned 207,417 BE shares valued at approximately $59.97 million.
3
Meiji Yasuda’s Sempra Energy (SRE) stake was a new position in Q2, totaling 17,951 shares valued at roughly $1.66 million, signaling continued expansion into utilities within the U.S. equities slate.
4
Royal London Asset Management Ltd. amplified its SRE exposure in Q2, purchasing 464,801 shares valued at about $43.1 million, illustrating sustained institutional appetite in Sempra Energy alongside other hedge funds.
Meiji Yasuda Life Insurance Co is on a buying spree in the U.S. stock market. The Japanese insurer boosted its Edwards Lifesciences stake by 39.1% to 24,900 shares in the second quarter, worth $2.25 million. It also made new bets on Sempra Energy and Bloom Energy, signaling a broad appetite for stakes in medical devices, utilities, and clean energy companies.
The moves mirror a broader trend: other major institutional investors are piling into these same stocks. Royal London Asset Management spent $43.1 million on Sempra Energy in Q2, buying 464,801 shares. Hedge funds and asset managers across the board are betting that these sectors will deliver strong returns.
Meiji Yasuda's Edwards Lifesciences Play Accelerates
Meiji Yasuda's Edwards Lifesciences position hit a new high in Q2. The insurer added 8,600 shares to its holdings, pushing the total to 24,900 shares. The 39.1% increase shows confidence in the medical device maker. Edwards Lifesciences makes heart valve systems and other surgical tools — staple products in hospitals worldwide.
Edwards Insiders Trim Stakes Despite Institutional Buying
Even as institutions buy, Edwards Lifesciences executives are selling. In August, VP Annette Bruls sold 2,644 shares at $89.98 per share, pocketing roughly $237,907. She still owns 17,984 shares worth about $1.62 million. The sale cut her stake by 12.82%. SEC filings also show VP Daniel J. Lippis sold 619 shares on August 11 at $92.03 each, netting about $56,967.
New Sempra Energy and Bloom Energy Positions Signal Sector Bets
Meiji Yasuda established a fresh Sempra Energy stake in Q2, buying 17,951 shares for roughly $1.66 million. Sempra is a major U.S. utilities and infrastructure company. The move marks Meiji Yasuda's entry into the utility space. watchlistnews.com reports that Royal London Asset Management went much bigger, snatching up 464,801 SRE shares for $43.1 million in the same quarter.
On the clean energy front, Meiji Yasuda bought 2,640 Bloom Energy shares in Q2, spending about $799,000. Bloom Energy makes fuel cells and energy storage systems. The purchases show the insurer is diversifying into growth sectors beyond traditional healthcare.
Executive Turnover at Bloom Energy Mirrors Broader Insider Activity
Bloom Energy's chief technology officer, Satish Chitoori, sold 2,837 shares on June 16 at $289.11 each, grossing about $820,205. After the sale, Chitoori retained 207,417 shares valued at roughly $59.97 million. The transaction signals that while institutions are buying, some insiders are locking in gains. These moves are typical when stock prices climb fast.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
7
Reach
24
A
AnonymousAuthor
